{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:20:47Z","timestamp":1777875647317,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007046","name":"Greater Milwaukee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021528","name":"Advancing a Healthier Wisconsin Endowment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015982","name":"Midwest Athletes Against Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcyt.2026.102779","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:26:05Z","timestamp":1773246365000},"page":"102779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved lentivector-modified hematopoietic stem cell transplantation in the Townes mouse model of sickle cell disease"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-784X","authenticated-orcid":false,"given":"Theresa A.","family":"Dlugi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-1657","authenticated-orcid":false,"given":"Juliana","family":"Alvarez-Argote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5913-0940","authenticated-orcid":false,"given":"Teresa","family":"Sundararajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Rybova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-1812","authenticated-orcid":false,"given":"Mary","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"McKillop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102779_bib0002","unstructured":"World Health Organization. Sickle cell disease. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sickle-cell-disease. Accessed March 27, 2026."},{"key":"10.1016\/j.jcyt.2026.102779_bib0003","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/ehm.10.22","article-title":"Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities","volume":"3","author":"Brandow","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jcyt.2026.102779_bib0005","first-page":"103","article-title":"A phase I study of hydroxyurea","volume":"29","author":"Thurman","year":"1963","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.jcyt.2026.102779_bib0006","first-page":"268","article-title":"Hydroxyurea increases fetal hemoglobin production in sickle cell anemia","volume":"97","author":"Platt","year":"1984","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.jcyt.2026.102779_bib0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7326\/0003-4819-72-3-327","article-title":"Symptomatic crises of sickle cell anemia treated by limited exchange transfusion","volume":"72","author":"Brody","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0008","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3324\/haematol.2020.270546","article-title":"Red cell transfusion and alloimmunization in sickle cell disease","volume":"106","author":"Linder","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102779_bib0009","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102779_bib0010","unstructured":"U.S. Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease. 2023.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. Accessed March 27, 2026."},{"key":"10.1016\/j.jcyt.2026.102779_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102779_bib0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0014","unstructured":"Bluebird Bio. Bluebird bio details plans for the commercial launch of LYFGENIA\u2122 gene therapy for patients ages 12 and older with sickle cell disease and a history of vaso-occlusive events. 2023.https:\/\/www.nasdaq.com\/press-release\/bluebird-bio-details-plans-for-the-commercial-launch-of-lyfgeniatm-gene-therapy-for. Accessed March 27, 2026."},{"key":"10.1016\/j.jcyt.2026.102779_bib0015","unstructured":"Institute for Clinical and Economic Review (ICER). ICER publishes final evidence report on gene therapies for sickle cell disease. 2023. https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-final-evidence-report-on-gene-therapies-for-sickle-cell-disease\/. Accessed March 27, 2026."},{"key":"10.1016\/j.jcyt.2026.102779_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.01.084","article-title":"Healthcare resource utilization and cost associated with allogeneic hematopoietic stem cell transplantation: a scoping review","volume":"30","author":"Kim","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0017","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102779_bib0018","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/bloodadvances.2024013693","article-title":"Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?","volume":"9","author":"Jones","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102779_bib0019","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.278.5339.873","article-title":"Knockout-transgenic mouse model of sickle cell disease","volume":"278","author":"Ryan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102779_bib0020","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease","volume":"278","author":"Paszty","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102779_bib0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102779_bib0022","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1089\/hum.2018.061","article-title":"Gene therapy for sickle cell disease: a lentiviral vector comparison study","volume":"29","author":"Urbinati","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0023","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","article-title":"Correction of a mouse model of sickle cell disease: lentiviral\/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells","volume":"102","author":"Levasseur","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102779_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2022.10.007","article-title":"Pathophysiological characterization of the Townes mouse model for sickle cell disease","volume":"254","author":"Alvarez-Argote","year":"2023","journal-title":"Transl Res"},{"key":"10.1016\/j.jcyt.2026.102779_bib0025","doi-asserted-by":"crossref","first-page":"27518","DOI":"10.1074\/jbc.M402578200","article-title":"A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin","volume":"279","author":"Levasseur","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcyt.2026.102779_bib0026","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1172\/JCI67930","article-title":"beta-globin gene transfer to human bone marrow for sickle cell disease","volume":"123","author":"Romero","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102779_bib0027","doi-asserted-by":"crossref","first-page":"e3567","DOI":"10.1002\/jgm.3567","article-title":"A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice","volume":"26","author":"Wang","year":"2024","journal-title":"J Gene Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0028","first-page":"570","article-title":"Comparison of submental blood collection with the retroorbital and submandibular methods in mice (Mus musculus)","volume":"55","author":"Regan","year":"2016","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.jcyt.2026.102779_bib0029","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2026.102779_bib0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1743-422X-10-240","article-title":"Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways","volume":"10","author":"Wang","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.jcyt.2026.102779_bib0031","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41467-021-20909-x","article-title":"Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice","volume":"12","author":"Wilkinson","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102779_bib0032","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector iterations and pre-clinical scale-up\/toxicity testing: targeting mobilized CD34(+) cells for correction of Fabry disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102779_bib0033","article-title":"Techniques for the detection of sickle cell disease: a review","volume":"12","author":"Arishi","year":"2021","journal-title":"Micromachines (Basel)"},{"key":"10.1016\/j.jcyt.2026.102779_bib0034","first-page":"987","article-title":"Relationship between morphologic characteristics of sickle cells and method of deoxygenation","volume":"104","author":"Asakura","year":"1984","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-017-0489-9","article-title":"Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing","volume":"10","author":"Wen","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102779_bib0036","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jcyt.2026.102779_bib0037","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-genom-120122-081037","article-title":"Sickle cell disease: from genetics to curative approaches","volume":"24","author":"Hardouin","year":"2023","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jcyt.2026.102779_bib0038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.omtn.2023.03.012","article-title":"Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies","volume":"32","author":"Brusson","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcyt.2026.102779_bib0039","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ymthe.2021.08.019","article-title":"Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease","volume":"30","author":"Ramadier","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/ebm.2025.10806","article-title":"Clinical data comparison for FDA-approved gene therapies in sickle cell disease","volume":"250","author":"Leonard","year":"2025","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0041","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.jcyt.2026.102779_bib0042","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","article-title":"Correction of sickle cell disease by homologous recombination in embryonic stem cells","volume":"108","author":"Wu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102779_bib0043","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102779_bib0044","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/jcmm.17201","article-title":"Influence of age on stem cells depends on the sex of the bone marrow donor","volume":"26","author":"Selle","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.958151","article-title":"Study of bone marrow microstructure in healthy young adults using intravoxel incoherent motion diffusion-weighted MRI","volume":"13","author":"Wu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jcyt.2026.102779_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295308","article-title":"Gender and the length of time since autologous hematopoietic stem cell transplantation\u2014what is their influence on the immune reconstitution in multiple myeloma patients?","volume":"18","author":"Popierz-Rydlewska","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102779_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.06.012","article-title":"Female sex is associated with improved long-term survival following allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Islam","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.jcyt.2026.102779_bib0048","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7150\/jca.89404","article-title":"Autologous stem cell transplant for refractory and relapsed peripheral T-cell lymphoma: a retrospective study in China","volume":"15","author":"Zhang","year":"2024","journal-title":"J Cancer"},{"key":"10.1016\/j.jcyt.2026.102779_bib0049","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2019.09.020","article-title":"Improved titer and gene transfer by lentiviral vectors using novel, small beta-globin locus control region elements","volume":"28","author":"Morgan","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ymthe.2024.01.015","article-title":"A new frontier: FDA approvals for gene therapy in sickle cell disease","volume":"32","author":"Leonard","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0051","first-page":"493","article-title":"Evading the immune response upon in vivo gene therapy with viral vectors","volume":"11","author":"Sack","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0052","volume":"27","author":"Yu","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0053","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102779_bib0054","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102779_bib0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/sj.mt.6300075","article-title":"Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells","volume":"15","author":"Liang","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102779_bib0056","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omtm.2023.01.003","article-title":"Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease","volume":"28","author":"Saleh","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102779_bib0057","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102779_bib0058","article-title":"Choice of donor source and conditioning regimen for hematopoietic stem cell transplantation in sickle cell disease","volume":"8","author":"Limerick","year":"1997","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcyt.2026.102779_bib0059","doi-asserted-by":"crossref","first-page":"eadp7690","DOI":"10.1126\/scitranslmed.adp7690","article-title":"Bone marrow transplant protects mice from sickle cell-mediated large artery remodeling","volume":"17","author":"Hatoum","year":"2025","journal-title":"Sci Transl Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:04:51Z","timestamp":1777586691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1465324926007401"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102779","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved lentivector-modified hematopoietic stem cell transplantation in the Townes mouse model of sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102779"}}